ArQule, Inc. to Present at 14th Annual Needham Healthcare Conference

WOBURN, Mass.--()--ArQule, Inc. (Nasdaq: ARQL) today announced that the Company will present at the 14th Annual Needham Healthcare Conference on Tuesday, April 14, 2015 at 3:00 p.m. The presentation will be web cast and may be accessed through the investor relations section of the Company’s website, http://investors.arqule.com/.

About ArQule

ArQule is a biotechnology company engaged in the research and development of next-generation, small-molecule cancer therapeutics. The Company’s targeted, broad-spectrum products and research programs are focused on key biological processes that are central to human cancers. ArQule’s lead product, in Phase 2 and Phase 3 clinical development, is tivantinib (ARQ 197), an oral, selective inhibitor of the c-MET receptor tyrosine kinase. The Company’s pipeline includes: ARQ 092, designed to inhibit the AKT serine/threonine kinase; ARQ 087, a multi-kinase inhibitor designed to preferentially inhibit the fibroblast growth factor receptor (FGFR) family; and ARQ 761, a Beta lapachone analog being evaluated as a promoter of NQ01-mediated programmed cancer cell necrosis. ArQule’s current discovery efforts are focused on the identification of novel kinase inhibitors, leveraging the Company’s proprietary library of compounds.

Contacts

ArQule, Inc.
William B. Boni, 781-994-0300
VP, Investor Relations/
Corp. Communications
www.ArQule.com

Release Summary

ArQule announces April 14, 2015 presentation at 14th Annual Needham Healthcare Conference.

Contacts

ArQule, Inc.
William B. Boni, 781-994-0300
VP, Investor Relations/
Corp. Communications
www.ArQule.com